Rocuronium pharmacodynamic models for published five pharmacokinetic models: age and sex are covariates in pharmacodynamic models

被引:5
|
作者
Masui, Kenichi [1 ,2 ]
Ishigaki, Sayaka [2 ,3 ]
Tomita, Atsuko [2 ]
Otake, Hiroshi [1 ]
机构
[1] Showa Univ, Sch Med, Dept Anesthesiol, Shinagawa Ku, Hatanodai 1-5-8, Tokyo 1428666, Japan
[2] Natl Def Med Coll, Dept Anesthesiol, Tokorozawa, Saitama 3598513, Japan
[3] Self Def Force Yokosuka Hosp, Dept Anesthesiol, Yokosuka, Kanagawa 2370071, Japan
关键词
Neuromuscular blockade; Rocuronium; Pharmacodynamics; TARGET-CONTROLLED INFUSION; NEUROMUSCULAR BLOCKADE; BROMIDE ORG-9426; TIME-COURSE; BOLUS; ANESTHESIA; HALOTHANE;
D O I
10.1007/s00540-018-2543-3
中图分类号
R614 [麻醉学];
学科分类号
100217 ;
摘要
Purpose Equilibration rate constant is necessary to calculate effect-site concentration, which is useful to control drug effect. We developed pharmacodynamic models for published five compartmental pharmacokinetic models published by Wierda, Szenohradszky, Cooper, Alvarez-Gomez, and McCoy. Methods We used 3848 train-of-four ratios from 15 male and nine female patients (21-76 years; 44-93 kg body weight; 148-181 cm height; and 17.3-29.8 kg/m(2) body mass index) as pharmacodynamic measures, which were collected at the start of 0.6 mg/kg rocuronium administration until the end of the surgery. Effect compartment was assumed to be connected to central compartment of the pharmacokinetic model with equilibration rate constant (k(e0)). Sigmoid E-max model was fitted to describe the relationship between train-of-four ratio and effect-site concentration. Age, sex, and body mass index were assessed as possible covariates of the following model parameters: k(e0), effect-site concentration for half of maximum effect, and the steepness of the effect-site concentration versus effect relationship. Results The duration of neuromuscular monitoring was 69 (37-129) [median (range)] min. All pharmacodynamic models included age and three included sex as significant covariates. K-e0 values ranged between 0.0820 and 0.247 depending on the pharmacokinetic model. The time-courses of the effect-site concentration were similar among the pharmacodynamic models for Wierda, Cooper, and Alvarez-Gomez pharmacokinetic models, which were lower than that for the Szenohradszky pharmacokinetic model. Conclusion Each pharmacodynamic model with the corresponding pharmacokinetic model can be described the time course of rocuronium effect appropriately. The required effect-site concentration of rocuronium for a pharmacodynamic effect was depending on the applied models.
引用
收藏
页码:709 / 716
页数:8
相关论文
共 50 条
  • [11] Pharmacokinetic-pharmacodynamic models for inhaled anaesthetics
    Kreuer, S.
    Bruhn, J.
    Wilhelm, W.
    Bouillon, T.
    ANAESTHESIST, 2007, 56 (06): : 538 - 556
  • [12] Deterministic identifiability of population pharmacokinetic and pharmacokinetic-pharmacodynamic models
    Siripuram, Vijay K.
    Wright, Daniel F. B.
    Barclay, Murray L.
    Duffull, Stephen B.
    JOURNAL OF PHARMACOKINETICS AND PHARMACODYNAMICS, 2017, 44 (05) : 415 - 423
  • [13] BUILDING POPULATION PHARMACOKINETIC PHARMACODYNAMIC MODELS .1. MODELS FOR COVARIATE EFFECTS
    MANDEMA, JW
    VEROTTA, D
    SHEINER, LB
    JOURNAL OF PHARMACOKINETICS AND BIOPHARMACEUTICS, 1992, 20 (05): : 511 - 528
  • [14] Exploring inductive linearization in population pharmacokinetic and pharmacodynamic models
    Fidler, Matt
    Xiong, Yuan
    Schoemaker, Rik
    Wilkins, Justin
    Trame, Mirjam N.
    Post, Teun
    Hooijmakers, Richard
    Wang, Wenping
    JOURNAL OF PHARMACOKINETICS AND PHARMACODYNAMICS, 2018, 45 : S116 - S116
  • [15] Pharmacokinetic-pharmacodynamic models for categorical toxicity data
    Diack, C
    Bois, FY
    REGULATORY TOXICOLOGY AND PHARMACOLOGY, 2005, 41 (01) : 55 - 65
  • [16] The Integrated Use of Pharmacokinetic and Pharmacodynamic Models for the Definition of Breakpoints
    H. Stass
    A. Dalhoff
    Infection, 2005, 33 : 29 - 35
  • [17] The integrated use of pharmacokinetic and pharmacodynamic models for the definition of breakpoints
    Stass, H
    Dalhoff, A
    INFECTION, 2005, 33 (Suppl 2) : 29 - 35
  • [18] Optimal designs for composed models in pharmacokinetic–pharmacodynamic experiments
    Holger Dette
    Andrey Pepelyshev
    Weng Kee Wong
    Journal of Pharmacokinetics and Pharmacodynamics, 2012, 39 : 295 - 311
  • [19] Pharmacokinetic/pharmacodynamic models for time courses of antibiotic effects
    Minichmayr, Iris K.
    Aranzana-Climent, Vincent
    Friberg, Lena E.
    INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS, 2022, 60 (03)
  • [20] Commentary: Stochastic phenomena in pharmacokinetic, pharmacodynamic, and pharmacogenomic models
    Siegel, RA
    Ramanathan, M
    AAPS JOURNAL, 2005, 7 (01): : E141 - E142